9 Meters Biopharma ( ) - 株価, ニュースと分析Nasdaq:NMTR

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NMTR 株式概要

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. 詳細

NMTR ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

収益は年間56.58%増加すると予測されています

リスク分析

意味のある時価総額がありません ( $3M )

キャッシュランウェイが1年未満である

収益が 100 万ドル未満 ( $0 )

マイナスの株主資本

+3 さらなるリスク

9 Meters Biopharma, Inc. 競合他社

SenesTech

NasdaqCM:SNES

US$2.4m

Akanda

NasdaqCM:AKAN

US$2.3m

InMed Pharmaceuticals

NasdaqCM:INM

US$3.3m

China Pharma Holdings

NYSEAM:CPHI

US$3.8m

価格と性能

の歴代最高値、変動、値下がりまとめ9 Meters Biopharma
過去の株価
現在の株価	US$0.20
52週高値	US$6.56
52週安値	US$0.18
ベータ	1.48
11ヶ月の変化	-72.75%
3ヶ月変化	-85.45%
1年変化	-96.00%
33年間の変化	-98.32%
5年間の変化	-99.85%
IPOからの変化	-99.83%

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

株主還元

	NMTR	US Pharmaceuticals	US 市場
7D	-71.1%	3.4%	1.6%
1Y	-96.0%	14.2%	32.3%

業界別リターン: NMTR過去 1 年間で14.2 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: NMTRは、過去 1 年間で32.3 % のリターンを上げたUS市場を下回りました。

価格変動

Is NMTR's price volatile compared to industry and market?
NMTR volatility
NMTR Average Weekly Movement	22.4%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

安定した株価: NMTRの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: NMTRの週次ボラティリティは、過去 1 年間で17%から22%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	10	Bethany Sensenig	www.9meters.com

9 Meters Biopharma, Inc. 基礎のまとめ

9 Meters Biopharma の収益と売上を時価総額と比較するとどうか。
NMTR 基礎統計学
時価総額	US$2.82m
収益（TTM）	-US$46.28m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-0.1x

PER（株価収益率

NMTR は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
NMTR 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$46.28m
収益	-US$46.28m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-3.20
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	-80.5%

NMTR の長期的なパフォーマンスは？

過去の実績と比較を見る

This company listing is no longer active

NMTR 株式概要

報酬

リスク分析

9 Meters Biopharma, Inc. 競合他社

NasdaqCM:SNES

US$2.4m

NasdaqCM:AKAN

US$2.3m

NasdaqCM:INM

US$3.3m

NYSEAM:CPHI

US$3.8m

価格と性能

最新ニュース

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index